Lutathera is a targeted radionuclide treatment that is developed to treat neuroendocrine 
tumor patients, more specifically, gastroenteropancreatic tumor patients. It gets internalized into the tumor and allows this radiation to cause damage to tumor cell within an ultimate goal of tumor shrinkage control progression. It's a relatively highly safe treatment and effective treatment in disease control. Neuroendocrine tumor patients don't have a lot of treatment options and when they fail the first line treatment, this is the most effective treatment available that could be offered to neuroendocrine tumor patients. It consists of four cycles separated approximately two months from one another. Altogether it's an eight-month treatment. Patient arrives at nuclear medicine early in the morning. And it takes usually five hours to complete the treatment. So it's a full day outpatient treatment for each cycle. When the patient is eligible and we decide to treat the patient at UVA, we contact the local physician and explain the process to them. At UVA, we are the only center offering this treatment in Virginia, except northern Virginia. We have a solid infrastructure consisting of multi-disciplinary expertise, nurses, coordinators, a treatment room dedicated for this treatment, radiation safety, monitoring, and a highly skilled nursing and physician team.